IP Library Granted Patent US 8,795,222
Granted Patent B2
US 8,795,222 · App. 13/006,218 · Granted Aug 5, 2014

Device and method for treatment of surface infections with nitric oxide

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,795,222
App. No.
13/006,218
Granted
Aug 5, 2014
Kind
B2
Abstract

Topical exposure of nitric oxide gas to wounds such as chronic non-healing wounds may be beneficial in promoting healing of the wound and in preparing the wound bed for further treatment and recovery. Nitric oxide gas may be used, for example, to reduce the microbial infection and burden on these wounds, manage exudate secretion by reducing inflammation, upregulate expression of endogenous collagenase to locally debride the wound, and regulate the formation of collagen. High concentration of nitric oxide ranging from about 160 to 400 ppm may be used without inducing toxicity in the healthy cells around a wound site. Additionally, exposure to the high concentration for a first treatment period reduces the microbial burden and inflammation at the wound site and increase collagenase expression to debride necrotic tissue at the wound site. After a first treatment period with high concentration of nitric oxide, a second treatment period at a lower concentration of nitric oxide preferably ranging from about 5-20 ppm may to provided to restore the balance of nitric oxide and induce collagen expression to aid in the closure of the wound.

Claims (29)

1. A method for debriding necrotic tissue located at a wound site of a subject, comprising:

exposing the wound site to exogenous nitric oxide gas at a concentration and for a period of time sufficient to increase expression of endogenous collagenase at the wound site,

wherein the concentration of exogenous nitric oxide gas is from about 120 ppm to about 400 ppm, and

wherein the period of time is from about 5 hours to about 72 hours.

2. The method of claim 1 , wherein the period of time and concentration of exogenous nitric oxide gas are sufficient to increase expression of endogenous gelatinase at the wound site.

3. The method of claim 1 , wherein the period of time and concentration of exogenous nitric oxide gas do not induce significant toxicity to healthy cells surrounding the wound site.

4. The method of claim 1 , wherein the concentration of exogenous nitric oxide gas is from about 200 ppm to about 250 ppm.

5. The method of claim 1 , additionally comprising mechanically debriding necrotic tissue located at the wound site following exposure to the exogenous nitric oxide gas.

6. The method of claim 1 , additionally comprising monitoring the expression of endogenous collagenase at the wound site during exposure to the exogenous nitric oxide gas.

7. A method for debriding necrotic tissue located at a wound site of a subject, comprising:

providing a flow-controlled source of gas containing exogenous nitric oxide; and

exposing the wound site to exogenous nitric oxide gas from the flow-controlled source of gas at a concentration and for a period of time sufficient to increase expression of endogenous collagenase at the wound site;

wherein the increased expression of endogenous collagenase at the wound site contributes to debriding of the necrotic tissue;

wherein the concentration of exogenous nitric oxide gas is from about 120 ppm to about 400 ppm; and

wherein the period of time is from about 5 hours to about 72 hours.

8. The method of claim 7 , wherein the period of time and concentration of exogenous nitric oxide gas are sufficient to increase expression of endogenous gelatinase at the wound site.

9. The method of claim 7 , wherein the period of time and concentration of exogenous nitric oxide gas do not induce significant toxicity to healthy cells surrounding the wound site.

10. The method of claim 7 , wherein the concentration of exogenous nitric oxide gas is from about 200 ppm to about 250 ppm.

11. The method of claim 7 , additionally comprising mechanically debriding necrotic tissue located at the wound site following exposure to the exogenous nitric oxide gas.

12. The method of claim 7 , additionally comprising monitoring the expression of endogenous collagenase at the wound site during exposure to the exogenous nitric oxide gas.

13. The method of claim 7 , additionally comprising grafting skin onto the wound site.

14. A method of managing exudate from necrotic tissue at a wound site of a subject, comprising:

exposing the wound site to exogenous nitric oxide gas at a concentration and for a period of time sufficient to reduce inflammation at the wound site, wherein the concentration of exogenous nitric oxide gas is from about 120 ppm to about 400 ppm, and

wherein the period of time is from about 5 hours to about 72 hours.

15. The method of claim 14 , additionally comprising providing a flow-controlled source of gas containing exogenous nitric oxide.

16. The method of claim 14 , additionally comprising cleaning the wound site prior to exposing the wound site to the exogenous nitric oxide gas.

17. The method of claim 14 , additionally comprising applying a gas permeable dressing to the wound site prior to exposing the wound site to the exogenous nitric oxide gas.

18. The method of claim 14 , wherein the period of time and concentration of exogenous nitric oxide gas do not induce significant toxicity to healthy cells surrounding the wound site.

19. The method of claim 14 , wherein the concentration of exogenous nitric oxide gas is from about 200 ppm to about 250 ppm.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2025
From: SENSORMEDICS CORPORATION
To: ZOLL MEDICAL CORPORATION
Reel/Frame 072869/0633 →
SECURITY INTEREST Recorded May 9, 2019
From: SENSORMEDICS CORPORATION
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 049126/0905 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2018
From: AIT THERAPEUTICS, INC.
To: ADVANCED INHALATION THERAPIES (AIT) LTD.
Reel/Frame 047562/0295 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2018
From: ADVANCED INHALATION THERAPIES (AIT) LTD.
To: AIT THERAPEUTICS, INC.
Reel/Frame 046234/0061 →
FIRST LIEN SECURITY AGREEMENT Recorded Apr 18, 2018
From: SENSORMEDICS CORPORATION
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 045968/0865 →
SECOND LIEN SECURITY AGREEMENT Recorded Apr 18, 2018
From: SENSORMEDICS CORPORATION
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 045782/0851 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2017
From: PULMONOX TECHNOLOGIES CORPORATION
To: ADVANCED INHALATION THERAPIES (AIT) LTD.
Reel/Frame 043779/0488 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2014
From: STENZLER, ALEX
To: SENSORMEDICS CORPORATION
Reel/Frame 033019/0888 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2014
From: MILLER, CHRISTOPHER C.
To: PULMONOX TECHNOLOGIES CORPORATION
Reel/Frame 033020/0026 →